Medicinal plant-based drug delivery system for inflammatory bowel disease
Frontiers in Pharmacology · 23.03.2023 · 14
DOI: 10.3389/fphar.2023.1158945 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 23.03.2023. Verfasst von Ningcen Li und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Academy of Chinese Medical Sciences.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) is a chronic recurrent intestinal disease. The incidence rate of IBD is increasing year by year, which seriously endangers human health worldwide. More and more studies have shown that medicinal plants or their main phytochemicals have great potential in the treatment of intestinal diseases. However, the disadvantages of low oral absorption rate, low biological distribution and low systemic bioavailability limit their clinical application to a certain extent. In recent years, the application of nanotechnology has made it possible to treat IBD. Nanoparticles (NPs) drug delivery system has attracted special attention in the treatment of IBD due to its small size, low immunogenicity, surface modification diversity, targeting and other advantages. Synthetic nanoparticles and extracellular vehicles (EVs) can deliver drug components to colon, and play a role in anti-inflammation, regulation of oxidative stress, improvement of intestinal flora, etc. In addition, some medicinal plants can secrete EVs by themselves, and carry biological molecules with therapeutic effects to act on the intestine. Some clinical trials to evaluate the safety, tolerance, toxicity and effectiveness of EVs-loaded drugs in IBD are also progressing steadily. This review introduces that synthetic nanoparticles and medicinal plants derived EVs can play an important role in the treatment of IBD by carrying the effective active phytochemicals of medicinal plants, and discuss the limitations of current research and future research needs, providing a scientific and reliable basis and perspective for further clinical application and promotion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Qingdao Hospital of Traditional Chinese Medicine (Qingdao Hiser Hospital), Qingdao, Shandong, China.
- Binhai New Area Hospital of TCM, Fourth Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- School of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, China.
Förderung
- China Academy of Chinese Medical Sciences
Zitieren
APA
Li, N., Wang, M., Lyu, Z., Shan, K., Chen, Z., Chen, B., Chen, Y., Hu, X., Dou, B., Zhang, J., Wang, L., Zhao, T., & Li, H. (2023). Medicinal plant-based drug delivery system for inflammatory bowel disease. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1158945
Vancouver
Li N, Wang M, Lyu Z, Shan K, Chen Z, Chen B, et al. Medicinal plant-based drug delivery system for inflammatory bowel disease. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1158945
BibTeX
@article{Li2023,
author = {Li, Ningcen and Wang, Meijuan and Lyu, Zhongxi and Shan, Kai and Chen, Zelin and Chen, Bo and Chen, Yong and Hu, Xiyou and Dou, Baomin and Zhang, Jingyu and Wang, Lifen and Zhao, Tianyi and Li, Hongjiao},
title = {Medicinal plant-based drug delivery system for inflammatory bowel disease},
journal = {Frontiers in Pharmacology},
year = {2023},
volume = {14},
doi = {10.3389/fphar.2023.1158945}
}
EUVIMED